- Trial phase
- Filed/PDUFA (BLA accepted by FDA)
- Time to market
- PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
- Why 8/10
- The next hard, dated catalyst is the FDA PDUFA decision for ozekibart in unresectable or metastatic conventional chondrosarcoma on April14, 2027. This represents a binary approval/rejection decision on the company's lead asset within ~5 months, warranting an 8 on the impact scale.
The next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.
Price Chart
Executive Summary
Ozekibart (formerly INBRX-109) is Inhibrx Biosciences' lead drug candidate, a precision-engineered antibody that activates death receptor 5 (DR5) to trigger cancer cell death. Its BLA for unresectable or metastatic conventional chondrosarcoma -- a rare bone cancer with no approved systemic therapies -- was accepted by the FDA in June2026 with a PDUFA date of April14, 2027. A registrational trial showed ozekibart reduced the risk of disease progression or death by 52% versus placebo. The stock surged over 70% on that readout in October2025. Inhibrx filed a $150M at-the-market equity offering on November13,2026 alongside Q3 results showing $199.5M cash, $275M debt, and a $38.7M quarterly burn. Short interest is elevated at ~23% of shares outstanding. Analyst consensus is strongly bullish with a mean price target of $266.67, implying ~204% upside from the recent $87.75 close. CEO Mark Lappe made ~$1.5M in open-market purchases in September-October2026.
How It Works
Ozekibart is a precision-engineered antibody that activates death receptor5 (DR5) on the surface of cancer cells. DR5 activation triggers a self-destruct signal (apoptosis) preferentially in tumor cells, causing them to die. It is designed as a tetravalent (four-armed) antibody to more potently cluster and activate DR5 compared to natural or simpler antibodies.
Trial Status
Positive registrational Phase 2/3 topline results announced October23,2025. BLA submitted in Q22026 and accepted by FDA with no filing review issues on June15,2026. PDUFA goal date set for April14,2027. Also in Phase1/2 for late-line colorectal cancer and Phase2 for refractory Ewing sarcoma.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA decision for ozekibart in unresectable or metastatic conventional chondrosarcoma on April14,2027
- Potential FDA Advisory Committee meeting (date not yet set)
- Up to $150M in ATM equity sales that could pressure the stock
- Update on accelerated approval pathway discussion with FDA for refractory Ewing sarcoma
- Ongoing Phase1/2 colorectal cancer data updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Inhibrx Biosciences, Inc. PRESS-RELEASE INBX ·Originating report